Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STP1002 in Advanced Solid Tumors
NCT04505839Phase 1Completed
- Sponsor
- ST Pharm
- Start
- Jul 2020
- Primary completion
- Mar 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of basroparib in solid tumor (advanced stage), colorectal cancer (CRC), non-small cell lung cancer (NSCLC) and 3 more, sponsored by ST Pharm. Primary endpoint: Dose limiting toxicities at 28 days. Started Jul 2020; status: completed.
02
Drugs
basroparib
03
Conditions
solid tumor (advanced stage)colorectal cancer (CRC)non-small cell lung cancer (NSCLC)gastric cancer (GC)renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT04505839.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04505839.